{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T08:17:41Z","timestamp":1793521061683,"version":"4.5.0"},"reference-count":56,"publisher":"Oxford University Press (OUP)","issue":"44","license":[{"start":{"date-parts":[[2024,8,30]],"date-time":"2024-08-30T00:00:00Z","timestamp":1724976000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004191","name":"Novo Nordisk","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004191","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004359","name":"Swedish Research Council","doi-asserted-by":"publisher","award":["2023-01807"],"award-info":[{"award-number":["2023-01807"]}],"id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]},{"name":"US National Institute of Health","award":["NIH R01DK115534"],"award-info":[{"award-number":["NIH R01DK115534"]}]},{"DOI":"10.13039\/501100003793","name":"Swedish Heart and Lung Foundation","doi-asserted-by":"publisher","award":["20230371"],"award-info":[{"award-number":["20230371"]}],"id":[{"id":"10.13039\/501100003793","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Region Stockholm","award":["FoUI-986028"],"award-info":[{"award-number":["FoUI-986028"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,11,21]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background and Aims<\/jats:title>\n                  <jats:p>The burden and outcomes of inflammation in patients with atherosclerotic cardiovascular disease (ASCVD) are not well defined beyond the controlled settings of trials and research cohorts.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>This was an observational study of ASCVD adults undergoing C-reactive protein testing in Stockholm\u2019s healthcare (2007\u201321). After excluding C-reactive protein tests associated with acute illness or medications\/conditions that bias C-reactive protein interpretation, systemic inflammation was evaluated over a 3-month ascertainment window. Determinants of C-reactive protein \u2265 2\u2005mg\/L were explored with logistic regression. C-reactive protein categories were compared via negative-binomial\/Cox regression for subsequent healthcare resource utilization and occurrence of major adverse cardiovascular events, heart failure hospitalization, and death.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>A total of 84 399 ASCVD adults were included (46% female, mean age 71 years, 59% with C-reactive protein \u2265 2\u2005mg\/L). Female sex, older age, lower kidney function, albuminuria, diabetes, hypertension, and recent anaemia were associated with higher odds of C-reactive protein \u2265 2\u2005mg\/L. The use of renin\u2013angiotensin system inhibitors, antiplatelets, and lipid-lowering therapy was associated with lower odds. Over a median of 6.4 years, compared with C-reactive protein &amp;lt; 2\u2005mg\/L, patients with C-reactive protein \u2265 2\u2005mg\/L had higher rates of hospitalizations, days spent in hospital, outpatient consultations, and dispensed medications (P &amp;lt; .05 for all). They also had a higher rate of major adverse cardiovascular events [hazard ratio (HR) 1.30; 95% confidence interval (CI) 1.27\u20131.33], heart failure (HR 1.24; 95% CI 1.20\u20131.30), and death (HR 1.35; 95% CI 1.31\u20131.39). Results were consistent across subgroups and granular C-reactive protein categories and robust to the exclusion of extreme C-reactive protein values or early events.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Three in five adults with ASCVD have systemic inflammation, which is associated with excess healthcare resource utilization and increased rates of cardiovascular events and death.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/eurheartj\/ehae557","type":"journal-article","created":{"date-parts":[[2024,8,30]],"date-time":"2024-08-30T14:53:28Z","timestamp":1725029608000},"page":"4719-4730","source":"Crossref","is-referenced-by-count":88,"title":["Systemic inflammation and health outcomes in patients receiving treatment for atherosclerotic cardiovascular disease"],"prefix":"10.1093","volume":"45","author":[{"given":"Faizan","family":"Mazhar","sequence":"first","affiliation":[{"name":"Department of Medical Epidemiology and Biostatistics, Campus Solna, Karolinska Institutet , Nobels v\u00e4g 12A, 171 65 Stockholm ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6716-1157","authenticated-orcid":false,"given":"Anne-Laure","family":"Faucon","sequence":"additional","affiliation":[{"name":"Department of Medical Epidemiology and Biostatistics, Campus Solna, Karolinska Institutet , Nobels v\u00e4g 12A, 171 65 Stockholm ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edouard L","family":"Fu","sequence":"additional","affiliation":[{"name":"Department of Medical Epidemiology and Biostatistics, Campus Solna, Karolinska Institutet , Nobels v\u00e4g 12A, 171 65 Stockholm ,","place":["Sweden"]},{"name":"Department of Clinical Epidemiology, Leiden University Medical Center , Leiden ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karolina E","family":"Szummer","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Karolinska Institutet, Karolinska University Hospital , Huddinge, Stockholm ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jimmi","family":"Mathisen","sequence":"additional","affiliation":[{"name":"Novo Nordisk A\/S , S\u00f8borg ,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sofia","family":"Gerward","sequence":"additional","affiliation":[{"name":"Novo Nordisk A\/S , S\u00f8borg ,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon Bertram","family":"Reuter","sequence":"additional","affiliation":[{"name":"Novo Nordisk A\/S , S\u00f8borg ,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6141-634X","authenticated-orcid":false,"given":"Nikolaus","family":"Marx","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine I, RWTH Aachen University , Aachen ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5546-262X","authenticated-orcid":false,"given":"Roxana","family":"Mehran","sequence":"additional","affiliation":[{"name":"Mount Sinai School of Medicine, Mount Sinai Health System , New York City, NY ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4763-2024","authenticated-orcid":false,"given":"Juan-Jesus","family":"Carrero","sequence":"additional","affiliation":[{"name":"Department of Medical Epidemiology and Biostatistics, Campus Solna, Karolinska Institutet , Nobels v\u00e4g 12A, 171 65 Stockholm ,","place":["Sweden"]},{"name":"Division of Nephrology, Department of Clinical Sciences, Danderyd Hospital , Danderyd ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,8,30]]},"reference":[{"key":"2024112100185388200_ehae557-B1","doi-asserted-by":"publisher","first-page":"e153","DOI":"10.1161\/cir.0000000000001052","article-title":"Heart disease and stroke statistics-2022 update: a report from the American Heart Association","volume":"145","author":"Tsao","year":"2022","journal-title":"Circulation"},{"key":"2024112100185388200_ehae557-B2","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1161\/circulationaha.116.021314","article-title":"Distribution of estimated 10-year risk of recurrent vascular events and residual risk in a secondary prevention population","volume":"134","author":"Kaasenbrood","year":"2016","journal-title":"Circulation"},{"key":"2024112100185388200_ehae557-B3","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1161\/CIRCULATIONAHA.118.034645","article-title":"Residual inflammatory risk on treatment with PCSK9 inhibition and statin therapy","volume":"138","author":"Pradhan","year":"2018","journal-title":"Circulation"},{"key":"2024112100185388200_ehae557-B4","doi-asserted-by":"publisher","first-page":"1897","DOI":"10.1056\/NEJMoa0707402","article-title":"Genetically elevated C-reactive protein and ischemic vascular disease","volume":"359","author":"Zacho","year":"2008","journal-title":"N Engl J Med"},{"key":"2024112100185388200_ehae557-B5","doi-asserted-by":"publisher","first-page":"e127","DOI":"10.1161\/circ.104.22.e127","article-title":"High-sensitivity C-reactive protein: potential adjunct for global risk assessment in the primary prevention of cardiovascular disease","volume":"104","author":"Guijarro","year":"2001","journal-title":"Circulation"},{"key":"2024112100185388200_ehae557-B6","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N Engl J Med"},{"key":"2024112100185388200_ehae557-B7","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","article-title":"Antiinflammatory therapy with canakinumab for atherosclerotic disease","volume":"377","author":"Ridker","year":"2017","journal-title":"N Engl J Med"},{"key":"2024112100185388200_ehae557-B8","doi-asserted-by":"publisher","first-page":"2497","DOI":"10.1056\/NEJMoa1912388","article-title":"Efficacy and safety of low-dose colchicine after myocardial infarction","volume":"381","author":"Tardif","year":"2019","journal-title":"N Engl J Med"},{"key":"2024112100185388200_ehae557-B9","doi-asserted-by":"publisher","first-page":"1838","DOI":"10.1056\/NEJMoa2021372","article-title":"Colchicine in patients with chronic coronary disease","volume":"383","author":"Nidorf","year":"2020","journal-title":"N Engl J Med"},{"key":"2024112100185388200_ehae557-B10","doi-asserted-by":"publisher","first-page":"2765","DOI":"10.1093\/eurheartj\/ehab115","article-title":"Efficacy and safety of low-dose colchicine in patients with coronary disease: a systematic review and meta-analysis of randomized trials","volume":"42","author":"Fiolet","year":"2021","journal-title":"Eur Heart J"},{"key":"2024112100185388200_ehae557-B11","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1136\/bmj.321.7255.199","article-title":"Low grade inflammation and coronary heart disease: prospective study and updated meta-analyses","volume":"321","author":"Danesh","year":"2000","journal-title":"BMJ"},{"key":"2024112100185388200_ehae557-B12","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/s0140-6736(09)61717-7","article-title":"C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis","volume":"375","author":"Kaptoge","year":"2010","journal-title":"Lancet"},{"key":"2024112100185388200_ehae557-B13","doi-asserted-by":"publisher","first-page":"483","DOI":"10.7326\/0003-4819-151-7-200910060-00009","article-title":"C-reactive protein as a risk factor for coronary heart disease: a systematic review and meta-analyses for the U.S. preventive services task force","volume":"151","author":"Buckley","year":"2009","journal-title":"Ann Intern Med"},{"key":"2024112100185388200_ehae557-B14","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1056\/NEJMoa1107477","article-title":"C-reactive protein, fibrinogen, and cardiovascular disease prediction","volume":"367","author":"Emerging Risk Factors Collaboration","year":"2012","journal-title":"N Engl J Med"},{"key":"2024112100185388200_ehae557-B15","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1093\/eurheartj\/ehu059","article-title":"C-reactive protein and risk of cardiovascular and all-cause mortality in 268 803 East Asians","volume":"35","author":"Sung","year":"2014","journal-title":"Eur Heart J"},{"key":"2024112100185388200_ehae557-B16","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.ijcard.2018.02.027","article-title":"The prognostic value of high sensitivity C-reactive protein in a multi-ethnic population after &gt;10\u202fyears of follow-up: the Multi-Ethnic Study of Atherosclerosis (MESA)","volume":"264","author":"Cainzos-Achirica","year":"2018","journal-title":"Int J Cardiol"},{"key":"2024112100185388200_ehae557-B17","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1016\/j.jacc.2021.07.016","article-title":"High-sensitivity C-reactive protein modifies the cardiovascular risk of lipoprotein(a): multi-ethnic study of atherosclerosis","volume":"78","author":"Zhang","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"2024112100185388200_ehae557-B18","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.ahj.2017.08.002","article-title":"Biochemical risk markers and 10-year incidence of atherosclerotic cardiovascular disease: independent predictors, improvement in pooled cohort equation, and risk reclassification","volume":"193","author":"Akintoye","year":"2017","journal-title":"Am Heart J"},{"key":"2024112100185388200_ehae557-B19","doi-asserted-by":"publisher","first-page":"e012638","DOI":"10.1161\/jaha.119.012638","article-title":"hsCRP level and the risk of death or recurrent cardiovascular events in patients with myocardial infarction: a healthcare-based study","volume":"8","author":"Carrero","year":"2019","journal-title":"J Am Heart Assoc"},{"key":"2024112100185388200_ehae557-B20","doi-asserted-by":"publisher","first-page":"4101","DOI":"10.1093\/eurheartj\/ehy633","article-title":"Residual inflammatory risk and the impact on clinical outcomes in patients after percutaneous coronary interventions","volume":"39","author":"Kalkman","year":"2018","journal-title":"Eur Heart J"},{"key":"2024112100185388200_ehae557-B21","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.cjca.2021.10.007","article-title":"Relationship of serial high-sensitivity C-reactive protein changes to long-term clinical outcomes in stabilised patients after myocardial infarction","volume":"38","author":"Lee","year":"2022","journal-title":"Can J Cardiol"},{"key":"2024112100185388200_ehae557-B22","doi-asserted-by":"publisher","first-page":"2827","DOI":"10.1161\/STROKEAHA.120.033152","article-title":"Residual inflammatory risk predicts poor prognosis in acute ischemic stroke or transient ischemic attack patients","volume":"52","author":"Li","year":"2021","journal-title":"Stroke"},{"key":"2024112100185388200_ehae557-B23","doi-asserted-by":"publisher","first-page":"2258","DOI":"10.1111\/ene.15344","article-title":"Association of residual inflammatory risk with stroke recurrence in patients with acute ischaemic stroke or transient ischaemic attack","volume":"29","author":"Liu","year":"2022","journal-title":"Eur J Neurol"},{"key":"2024112100185388200_ehae557-B24","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.amjcard.2021.12.042","article-title":"Effect of elevated C-reactive protein on outcomes after complex percutaneous coronary intervention for angina pectoris","volume":"168","author":"Camaj","year":"2022","journal-title":"Am J Cardiol"},{"key":"2024112100185388200_ehae557-B25","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/j.jacasi.2021.11.014","article-title":"Residual inflammatory risk and its association with events in East Asian patients after coronary intervention","volume":"2","author":"Ahn","year":"2022","journal-title":"JACC Asia"},{"key":"2024112100185388200_ehae557-B26","doi-asserted-by":"publisher","first-page":"e14000","DOI":"10.1111\/eci.14000","article-title":"Prognostic role of CRP-independent inflammatory patterns in patients undergoing primary percutaneous interventions","volume":"53","author":"Dossi","year":"2023","journal-title":"Eur J Clin Invest"},{"key":"2024112100185388200_ehae557-B27","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1186\/s12933-023-01826-3","article-title":"Effect of dual residual risk of cholesterol and inflammation on all-cause mortality in patients with cardiovascular disease","volume":"22","author":"Yang","year":"2023","journal-title":"Cardiovasc Diabetol"},{"key":"2024112100185388200_ehae557-B28","doi-asserted-by":"publisher","first-page":"2401","DOI":"10.1016\/j.jacc.2019.01.077","article-title":"Residual inflammatory risk in patients with low LDL cholesterol levels undergoing percutaneous coronary intervention","volume":"73","author":"Guedeney","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"2024112100185388200_ehae557-B29","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s00392-019-01511-0","article-title":"Residual inflammatory risk in coronary heart disease: incidence of elevated high-sensitive CRP in a real-world cohort","volume":"109","author":"Peikert","year":"2020","journal-title":"Clin Res Cardiol"},{"key":"2024112100185388200_ehae557-B30","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.amjcard.2023.03.025","article-title":"C-reactive protein and risk of cardiovascular events and mortality in patients with various cardiovascular disease locations","volume":"197","author":"Burger","year":"2023","journal-title":"Am J Cardiol"},{"key":"2024112100185388200_ehae557-B31","doi-asserted-by":"publisher","first-page":"2356","DOI":"10.1016\/j.jacc.2022.09.035","article-title":"Elevated C-reactive protein amplifies association of lipoprotein(a) with cardiovascular risk and clinical benefit of alirocumab","volume":"80","author":"Schwartz","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"2024112100185388200_ehae557-B32","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1001\/jamacardio.2020.2413","article-title":"Effect of C-reactive protein on lipoprotein(a)-associated cardiovascular risk in optimally treated patients with high-risk vascular disease: a prespecified secondary analysis of the ACCELERATE trial","volume":"5","author":"Puri","year":"2020","journal-title":"JAMA Cardiol"},{"key":"2024112100185388200_ehae557-B33","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1177\/2396987320984003","article-title":"Interleukin-6, C-reactive protein, fibrinogen, and risk of recurrence after ischaemic stroke: systematic review and meta-analysis","volume":"6","author":"McCabe","year":"2021","journal-title":"Eur Stroke J"},{"key":"2024112100185388200_ehae557-B34","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1016\/S0140-6736(23)00215-5","article-title":"Inflammation and cholesterol as predictors of cardiovascular events among patients receiving statin therapy: a collaborative analysis of three randomised trials","volume":"401","author":"Ridker","year":"2023","journal-title":"Lancet"},{"key":"2024112100185388200_ehae557-B35","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/j.ejvs.2017.05.009","article-title":"Systematic review and meta-analysis of the association between C-reactive protein and major cardiovascular events in patients with peripheral artery disease","volume":"54","author":"Singh","year":"2017","journal-title":"Eur J Vasc Endovasc Surg"},{"key":"2024112100185388200_ehae557-B36","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1111\/joim.13418","article-title":"The Stockholm CREAtinine Measurements (SCREAM) project: fostering improvements in chronic kidney disease care","volume":"291","author":"Carrero","year":"2022","journal-title":"J Intern Med"},{"key":"2024112100185388200_ehae557-B37","doi-asserted-by":"publisher","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","article-title":"A new equation to estimate glomerular filtration rate","volume":"150","author":"Levey","year":"2009","journal-title":"Ann Intern Med"},{"key":"2024112100185388200_ehae557-B38","doi-asserted-by":"publisher","first-page":"825","DOI":"10.7326\/0003-4819-158-11-201306040-00007","article-title":"Evaluation and management of chronic kidney disease: synopsis of the kidney disease: improving global outcomes 2012 clinical practice guideline","volume":"158","author":"Stevens","year":"2013","journal-title":"Ann Intern Med"},{"key":"2024112100185388200_ehae557-B39","doi-asserted-by":"publisher","first-page":"A11398","DOI":"10.1161\/circ.146.suppl_1.11398","article-title":"Abstract 11398: prevalence and characteristics of systemic inflammation in adults with atherosclerotic cardiovascular disease and chronic kidney disease: results from the national health and nutrition examination survey","volume":"146","author":"Nanna","year":"2022","journal-title":"Circulation"},{"key":"2024112100185388200_ehae557-B40","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.atherosclerosis.2019.08.014","article-title":"2019 ESC\/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk","volume":"290","author":"Mach","year":"2019","journal-title":"Atherosclerosis"},{"key":"2024112100185388200_ehae557-B41","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.4158\/CS-2020-0490","article-title":"Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the management of dyslipidemia and prevention of cardiovascular disease algorithm\u20142020 executive summary","volume":"26","author":"Handelsman","year":"2020","journal-title":"Endocr Pract"},{"key":"2024112100185388200_ehae557-B42","doi-asserted-by":"publisher","first-page":"e017793","DOI":"10.1161\/jaha.120.017793","article-title":"Financial toxicity in atherosclerotic cardiovascular disease in the United States: current state and future directions","volume":"9","author":"Khera","year":"2020","journal-title":"J Am Heart Assoc"},{"key":"2024112100185388200_ehae557-B43","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1186\/s12872-023-03518-y","article-title":"Economic burden of atherosclerotic cardiovascular disease: a matched case\u2013control study in more than 450,000 Swedish individuals","volume":"23","author":"Steen Carlsson","year":"2023","journal-title":"BMC Cardiovasc Disord"},{"key":"2024112100185388200_ehae557-B44","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1093\/eurheartj\/ehaa099","article-title":"Targeting cardiovascular inflammation: next steps in clinical translation","volume":"42","author":"Lawler","year":"2021","journal-title":"Eur Heart J"},{"key":"2024112100185388200_ehae557-B45","doi-asserted-by":"publisher","first-page":"754","DOI":"10.3389\/fimmu.2018.00754","article-title":"Role of C-reactive protein at sites of inflammation and infection","volume":"9","author":"Sproston","year":"2018","journal-title":"Front Immunol"},{"key":"2024112100185388200_ehae557-B46","doi-asserted-by":"publisher","first-page":"1715","DOI":"10.1093\/eurheartj\/ehac056","article-title":"Estimation of recurrent atherosclerotic cardiovascular event risk in patients with established cardiovascular disease: the updated SMART2 algorithm","volume":"43","author":"Hageman","year":"2022","journal-title":"Eur Heart J"},{"key":"2024112100185388200_ehae557-B47","doi-asserted-by":"publisher","first-page":"1720","DOI":"10.1093\/eurheartj\/ehw024","article-title":"Residual inflammatory risk: addressing the obverse side of the atherosclerosis prevention coin","volume":"37","author":"Ridker","year":"2016","journal-title":"Eur Heart J"},{"key":"2024112100185388200_ehae557-B48","doi-asserted-by":"publisher","first-page":"3227","DOI":"10.1093\/eurheartj\/ehab484","article-title":"2021 ESC guidelines on cardiovascular disease prevention in clinical practice","volume":"42","author":"Visseren","year":"2021","journal-title":"Eur Heart J"},{"key":"2024112100185388200_ehae557-B49","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1016\/S0140-6736(14)61368-4","article-title":"Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174\u2008000 participants in 27 randomised trials","volume":"385","author":"Cholesterol Treatment Trialists\u2019 (CTT) Collaboration","year":"2015","journal-title":"Lancet"},{"key":"2024112100185388200_ehae557-B50","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/s0140-6736(17)32814-3","article-title":"Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial","volume":"391","author":"Ridker","year":"2018","journal-title":"Lancet"},{"key":"2024112100185388200_ehae557-B51","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1182\/blood-2018-06-856500","article-title":"Anemia of inflammation","volume":"133","author":"Weiss","year":"2019","journal-title":"Blood"},{"key":"2024112100185388200_ehae557-B52","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1111\/dom.14601","article-title":"Improving the residual risk of renal and cardiovascular outcomes in diabetic kidney disease: a review of pathophysiology, mechanisms, and evidence from recent trials","volume":"24","author":"Chaudhuri","year":"2022","journal-title":"Diabetes Obes Metab"},{"key":"2024112100185388200_ehae557-B53","doi-asserted-by":"publisher","first-page":"1775","DOI":"10.1016\/j.ekir.2021.04.023","article-title":"Chronic inflammation in chronic kidney disease progression: role of Nrf2","volume":"6","author":"Stenvinkel","year":"2021","journal-title":"Kidney Int Rep"},{"key":"2024112100185388200_ehae557-B54","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1681\/asn.2016101066","article-title":"Immunologic effects of the renin-angiotensin system","volume":"28","author":"Crowley","year":"2017","journal-title":"J Am Soc Nephrol"},{"key":"2024112100185388200_ehae557-B55","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1038\/nri3452","article-title":"Activation and regulation of the inflammasomes","volume":"13","author":"Latz","year":"2013","journal-title":"Nat Rev Immunol"},{"key":"2024112100185388200_ehae557-B56","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1001\/jama.2009.954","article-title":"Genetic loci associated with C-reactive protein levels and risk of coronary heart disease","volume":"302","author":"Elliott","year":"2009","journal-title":"JAMA"}],"container-title":["European Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurheartj\/article-pdf\/45\/44\/4719\/60751116\/ehae557.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurheartj\/article-pdf\/45\/44\/4719\/60751116\/ehae557.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,21]],"date-time":"2024-11-21T00:19:14Z","timestamp":1732148354000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurheartj\/article\/45\/44\/4719\/7742419"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,30]]},"references-count":56,"journal-issue":{"issue":"44","published-online":{"date-parts":[[2024,8,30]]},"published-print":{"date-parts":[[2024,11,21]]}},"URL":"https:\/\/doi.org\/10.1093\/eurheartj\/ehae557","relation":{},"ISSN":["0195-668X","1522-9645"],"issn-type":[{"value":"0195-668X","type":"print"},{"value":"1522-9645","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,11,21]]},"published":{"date-parts":[[2024,8,30]]}}}